Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol Myers Squibb (BMY) increased its quarterly dividend to $0.63, marking 17 consecutive annual raises. The yield is 4.2% based on the current share price. Q2 EPS exceeded estimates, leading to raised 2026 guidance. Growth portfolio sales rose 15%, but older drugs like Revlimid and Pomalyst declined. The dividend's future depends on new drugs replacing Eliquis, which faces patent expiry in 2028. The company has $43.1 billion in debt.
How this was made
The 30-second read
Why it matters
Near-term dividend confidence is supported by guidance and cash-flow coverage, but the dominant risk is whether newer drugs (especially milvexian) can replace Eliquis before and after the 2028 LOE window.
Market read
Traders focused on dividend durability may use the coverage and guidance details to calibrate downside risk, while growth/pipeline watchers may treat milvexian timing as the next catalyst.
What to watch
The article does not quantify how much milvexian commercial ramp, pricing, and competitive dynamics could offset Eliquis step-down, nor does it detail potential cost or debt-service changes that could affect free cash flow.
Background
The article frames BMY’s quarterly dividend increase and yield, then links dividend sustainability to raised 2026 EPS guidance, cash flow, debt paydown, and the Eliquis patent expiry timeline.
Ticker impact
Article ties BMY’s dividend safety to its Q2 beat, raised 2026 non-GAAP EPS guidance, and Eliquis loss-of-exclusivity timing into 2027-2028.
Likely modest support for BMY as income investors focus on coverage below 40% of guided earnings, but upside is capped if Eliquis decline and milvexian timeline slip raise dividend-growth uncertainty.
The piece provides concrete guidance and cash-flow coverage metrics, then frames the key swing factor as Eliquis LOE in April 2028 and milvexian data timing in 2027.
Market effects
Reinforces the broader pharma income trade-off between dividend support from growth portfolios and earnings pressure from patent expiries.
Limited, primarily affects US large-cap pharma dividend and defensives sentiment.
Low, as the catalysts discussed are company-specific (Eliquis LOE and BMY pipeline timelines).
Counterpoint
The dividend coverage ratio can look comfortable while still being vulnerable to a faster-than-expected Eliquis decline or weaker-than-expected replacement uptake, making the “safe” framing overstated.
Key entities
- companyBristol Myers Squibb
Subject of the article, discussed for dividend yield, raised 2026 EPS guidance, cash flow, debt paydown, and Eliquis LOE risk.
- productEliquis
BMY’s anticoagulant facing loss of exclusivity in April 2028, with expected sales step-down in 2027.
- pipeline_assetmilvexian
BMY’s atrial fibrillation candidate positioned as a potential Eliquis replacement, with data timing referenced for 2027.
